The Viral And Non-Viral Vector Manufacturing Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
The global market size for viral and non-viral vector manufacturing has seen swift expansion recently. It is predicted to increase from $8.67 billion in 2024 to $10.3 billion the following year, with a Compound Annual Growth Rate (CAGR) of 18.8%.
The Viral And Non-Viral Vector Manufacturing Global Market Report 2024 predicts that by 2029, the market will grow to $22.06 billion, with a compound annual growth rate (CAGR) of 21.0%.
Download Your Free Sample of the 2025 Viral And Non-Viral Vector Manufacturing Market Report and Uncover Key Trends Now!The key drivers in the viral and non-viral vector manufacturing market are:
• Rising demand for gene therapies
• Expanding applications in rare disease treatment
• Increasing investments in biomanufacturing infrastructure
• Growing adoption of precision medicine
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
The key trends in the viral and non-viral vector manufacturing market are:
• The development of next-generation viral vectors is a major upcoming trend.
• There is an increasing use of CRISPR or cas9 technology in vector manufacturing.
• The industry is focusing more on scalable and cost-efficient manufacturing processes.
• Advancements in cell and gene therapy manufacturing technologies are significantly shaping the future.
The major players in the viral and non-viral vector manufacturing market are:
• Novartis AG
• Thermo Fisher Scientific Inc
North America was the largest region in the viral and non-viral vector manufacturing market in 2024